| Dr Richard Lee Endorf, MD | |
|
1200 College Dr, Rock Springs, WY 82901-5868 | |
| (307) 350-8577 | |
| (307) 875-8800 |
| Full Name | Dr Richard Lee Endorf |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 22 Years |
| Location | 1200 College Dr, Rock Springs, Wyoming |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871580266 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083A0100X | Preventive Medicine - Aerospace Medicine | 22629 (Nebraska) | Secondary |
| 2085R0202X | Radiology - Diagnostic Radiology | TL3366 (Wyoming) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Avera Sacred Heart Hospital | Yankton, SD | Hospital |
| Avera St Anthony's Hospital | O' neill, NE | Hospital |
| Avera Creighton Hospital | Creighton, NE | Hospital |
| Avera Gregory Hospital | Gregory, SD | Hospital |
| Wagner Community Memorial Hospital - Cah | Wagner, SD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sacred Heart Health Services | 6103729066 | 83 |
News Archive
The Cedars-Sinai Regenerative Medicine Institute has received a $2.5 million grant from the Department of Defense to conduct animal studies that, if successful, could provide the basis for a clinical trial of a gene therapy product for patients with Lou Gehrig's disease, also called amyotrophic lateral sclerosis, or ALS.
Researchers have identified two antibodies that protect mice against lethal infections of influenza B virus, report scientists at Washington University School of Medicine in St. Louis and Icahn School of Medicine at Mount Sinai.
Children living in disadvantaged neighbourhoods are more likely to succeed if they participate in a community-based prevention program, according to findings released recently from a multi-year research study based at Queen's University.
Genomic Health, Inc. today announced worldwide commercial availability of its Oncotype DX® colon cancer test, the first multigene expression test developed for the assessment of risk of recurrence in patients with stage II disease. The 12-gene advanced diagnostic test is clinically validated to predict individual recurrence risk in stage II colon cancer patients following surgery, as reported at the 2009 American Society of Clinical Oncology (ASCO) meeting.
› Verified 6 days ago
| Entity Name | Avera Queen Of Peace |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205359031 PECOS PAC ID: 9335050806 Enrollment ID: O20031229000301 |
News Archive
The Cedars-Sinai Regenerative Medicine Institute has received a $2.5 million grant from the Department of Defense to conduct animal studies that, if successful, could provide the basis for a clinical trial of a gene therapy product for patients with Lou Gehrig's disease, also called amyotrophic lateral sclerosis, or ALS.
Researchers have identified two antibodies that protect mice against lethal infections of influenza B virus, report scientists at Washington University School of Medicine in St. Louis and Icahn School of Medicine at Mount Sinai.
Children living in disadvantaged neighbourhoods are more likely to succeed if they participate in a community-based prevention program, according to findings released recently from a multi-year research study based at Queen's University.
Genomic Health, Inc. today announced worldwide commercial availability of its Oncotype DX® colon cancer test, the first multigene expression test developed for the assessment of risk of recurrence in patients with stage II disease. The 12-gene advanced diagnostic test is clinically validated to predict individual recurrence risk in stage II colon cancer patients following surgery, as reported at the 2009 American Society of Clinical Oncology (ASCO) meeting.
› Verified 6 days ago
| Entity Name | Sacred Heart Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861611683 PECOS PAC ID: 6103729066 Enrollment ID: O20040128000978 |
News Archive
The Cedars-Sinai Regenerative Medicine Institute has received a $2.5 million grant from the Department of Defense to conduct animal studies that, if successful, could provide the basis for a clinical trial of a gene therapy product for patients with Lou Gehrig's disease, also called amyotrophic lateral sclerosis, or ALS.
Researchers have identified two antibodies that protect mice against lethal infections of influenza B virus, report scientists at Washington University School of Medicine in St. Louis and Icahn School of Medicine at Mount Sinai.
Children living in disadvantaged neighbourhoods are more likely to succeed if they participate in a community-based prevention program, according to findings released recently from a multi-year research study based at Queen's University.
Genomic Health, Inc. today announced worldwide commercial availability of its Oncotype DX® colon cancer test, the first multigene expression test developed for the assessment of risk of recurrence in patients with stage II disease. The 12-gene advanced diagnostic test is clinically validated to predict individual recurrence risk in stage II colon cancer patients following surgery, as reported at the 2009 American Society of Clinical Oncology (ASCO) meeting.
› Verified 6 days ago
| Entity Name | Osmond General Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528140993 PECOS PAC ID: 4183689227 Enrollment ID: O20050429000536 |
News Archive
The Cedars-Sinai Regenerative Medicine Institute has received a $2.5 million grant from the Department of Defense to conduct animal studies that, if successful, could provide the basis for a clinical trial of a gene therapy product for patients with Lou Gehrig's disease, also called amyotrophic lateral sclerosis, or ALS.
Researchers have identified two antibodies that protect mice against lethal infections of influenza B virus, report scientists at Washington University School of Medicine in St. Louis and Icahn School of Medicine at Mount Sinai.
Children living in disadvantaged neighbourhoods are more likely to succeed if they participate in a community-based prevention program, according to findings released recently from a multi-year research study based at Queen's University.
Genomic Health, Inc. today announced worldwide commercial availability of its Oncotype DX® colon cancer test, the first multigene expression test developed for the assessment of risk of recurrence in patients with stage II disease. The 12-gene advanced diagnostic test is clinically validated to predict individual recurrence risk in stage II colon cancer patients following surgery, as reported at the 2009 American Society of Clinical Oncology (ASCO) meeting.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Richard Lee Endorf, MD 105 Grant Cir, Offutt A F B, NE 68113-4041 Ph: (402) 294-7345 | Dr Richard Lee Endorf, MD 1200 College Dr, Rock Springs, WY 82901-5868 Ph: (307) 350-8577 |
News Archive
The Cedars-Sinai Regenerative Medicine Institute has received a $2.5 million grant from the Department of Defense to conduct animal studies that, if successful, could provide the basis for a clinical trial of a gene therapy product for patients with Lou Gehrig's disease, also called amyotrophic lateral sclerosis, or ALS.
Researchers have identified two antibodies that protect mice against lethal infections of influenza B virus, report scientists at Washington University School of Medicine in St. Louis and Icahn School of Medicine at Mount Sinai.
Children living in disadvantaged neighbourhoods are more likely to succeed if they participate in a community-based prevention program, according to findings released recently from a multi-year research study based at Queen's University.
Genomic Health, Inc. today announced worldwide commercial availability of its Oncotype DX® colon cancer test, the first multigene expression test developed for the assessment of risk of recurrence in patients with stage II disease. The 12-gene advanced diagnostic test is clinically validated to predict individual recurrence risk in stage II colon cancer patients following surgery, as reported at the 2009 American Society of Clinical Oncology (ASCO) meeting.
› Verified 6 days ago
Dr. Jessika Silvia Dingwall, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1200 College Dr, Rock Springs, WY 82901 Phone: 307-350-8577 Fax: 307-875-8800 | |
Mary F Murphy, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1200 College Dr, Rock Springs, WY 82901 Phone: 307-352-8577 Fax: 307-875-8800 | |
Dr. Frederick L Matti, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1200 College Dr, Rock Springs, WY 82901 Phone: 786-621-3900 Fax: 307-875-8800 |